Hypericum perforatum extracts as potential antidepressants

Journal of Pharmacy and Pharmacology

Volumn 51, Issue 5, 1999, Pages 513-517

  Vitiello, Benedetto ^a  

^a NATIONAL INSTITUTE OF MENTAL HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMITRIPTYLINE; ANTIDEPRESSANT AGENT; HYPERICUM PERFORATUM EXTRACT; IMIPRAMINE; TRICYCLIC ANTIDEPRESSANT AGENT;

CLINICAL TRIAL; CONFERENCE PAPER; DEPRESSION; DIET SUPPLEMENTATION; DRUG EFFECT; DRUG EFFICACY; GASTROINTESTINAL SYMPTOM; HUMAN; MOOD; PHOTOSENSITIVITY DISORDER;

EID: 0032987555     PISSN: 00223573     EISSN: None     Source Type: Journal    
DOI: 10.1211/0022357991772781     Document Type: Conference Paper

References (20)

1. American Herbal Pharmacopoeia and Therapeutic Compendium (1997) St. John's Wort: Hypericum perforatum. American Herbal Pharmacopoeia
2. American Psychiatric Association: Diagnostic and Statistical Manual (1980) 3rd edn. American Psychiatric Association, Washington, DC
3. American Psychiatric Association: Diagnostic and Statistical Manual (1987) 3rd edn, revised. American Psychiatric Association, Washington, DC
4. American Psychiatric Association: Diagnostic and Statistical Manual (1994) 4th edn. American Psychiatric Association, Washington, DC
5. Biber, A., Fischer, H., Romer, A., Chatterjee, S. (1998) Oral bioavailability of hyperforin from hypericum extracts in rats and human volunteers. Pharmacopsychiatry 31: 36-43
6. Brockmoller, J., Reum, T., Bauer, S., Kerb, R., Hubner, W.-D., Roots, I. (1997) Hypericin and pseudohypericin: pharmacokinetics and effects on photosensitivity in humans. Pharmacopsychiatry 30: S94-101
7. Butterweck, V., Petereit, F., Winterhoff, H., Nahrstedt, A. (1998) Solubilized hypericin and pseudohypericin from Hypericum perforatum exert antidepressant activity in the forced swimming test. Planta Medica 64: 291-294
8. Chatterjee, S. S., Noldner, M., Koch, E., Erdelmeier, C. (1998) Antidepressant activity of Hypericum perforatum and hyperforin: the neglected possibility. Pharmacopsychiatry 31: 7-15
9. Cott, J. (1997) In vitro receptor binding and enzyme inhibition by Hypericum perforatum extract. Pharmacopsychiatry 30: S129-S134
10. Czekalla, J., Gastpar, M., Hubner, W.-D., Jager, D. (1997) The effect of Hypericum extract on cardiac conduction as seen in the electrocardiogram compared to that of imipramine. Pharmacopsychiatry 30: S86-S88
11. Laakman, G., Schule, C., Baghai, T., Kieser, M. (1998) St. John's wort in mild to moderate depression: the relevance of hyperforin for the clinical efficacy. Pharmacopsychiatry 31: S54-S59
12. Linde, K., Ramirez, G., Mulrow, C. D., Pauls, A., Weidenhammer, W., Melchart, D. (1996) St. John's wort for depression-an overview and meta-analysis of randomised clinical trials. Br. Med. J. 313: 253-258
13. Muller, W. E., Rolli, M., Schafer, C., Hafner, U. (1997) Effects of Hypericum extract (LI 160) in biochemical models of antidepressant activity. Pharmacopsychiatry 30: S102-S107
14. Muller, W. E., Singer, A., Wonnemann, M., Hafner, U., Rolli, M., Schafer, C. (1998) Hyperforin represents the neuro-transmitter reuptake inhibiting constituent of Hypericum extract. Pharmacopsychiatry 31: 7-15
15. Nahrstedt, A., Butterweck, V. (1997) Biologically active and other chemical constituents of Hypericum perforatum L. Pharmacopsychiatry 30: S129-S134
16. Staffeldt, B., Kerb, R., Brockmoller, J., Ploch, M., Roots, I. (1994) Pharmacokinetics of hypericin and pseudohypericin after oral intake of the Hypericum perforatum extract LI 160 in healthy volunteers. J. Geriatr. Psychiatry Neurol. 7: S47-S53
17. Vorbach, E. U., Arnoldt, K. H., Hubner, W.-D. (1997) Efficacy and tolerability of St. John's wort extract LI 160 versus imipramine in patients with severe depressive episodes according to ICD-10. Pharmacopsychiatry 30: S77-S80
18. Wagner, H., Bladt, S. (1994) Pharmaceutical quality of Hypericum extracts. J. Geriatr. Psychiatry Neurol. 7: S65-S68
19. Wheatley, D. (1997) LI 160, and extract of St. John's wort, versus amitriptyline in mildly to moderately depressed out-patients - a controlled 6-week trial. Pharmacopsychiatry 30: S77-S80
20. Woelk, H., Burkard, G., Grunwald, J. (1994) Benefits and risks of Hypericum extract LI 160: drug monitoring study with 3250 patients. J. Geriatr. Psychiatry Neurol. 7: S34-S38